Coronavirus | Opeds and editorials

Undermining ‘vaccination for all’

Just when the spread of COVID-19 has reached catastrophic proportions, with the daily case-load rising faster than that seen anywhere in the world since the beginning of the novel coronavirus pandemic, the Government of India has acted by unveiling a completely revamped vaccine strategy. Two key elements are the hallmark of this new strategy, which will be implemented from May 1. First, the phased roll-out of the vaccination drive initiated on January 16 under which the vaccine-eligible sections of the population were gradually increased, has now been extended to the entire adult population, namely, to those above 18 years. Second, and more importantly, a significant deregulation of the vaccine market has been effected and vaccine manufacturers have the freedom to sell 50% of their vaccine production to State governments and private hospitals, and at prices that can be substantially higher than that hitherto fixed by the government. A third element of the vaccine strategy, which was not announced formally, is a grant of ₹45 billion to the two vaccine manufacturers, the Serum Institute of India (SII) and Bharat Biotech, to boost their capacities.

Handing over the reins

The new vaccine strategy raises a number of questions, not the least from the manner in which the central government has given up its control over the market for vaccines, a key feature of the vaccine roll-out plans thus far. This issue assumes further significance since the Government of India is well aware, as all public authorities around the world are, about the significance of vaccinating every citizen in the country; “none of us will be safe until everyone is safe”. It is, therefore, vitally important that public health authorities in the country take an objective view of the realities of the country before adopting strategies for vaccine availability, for this is absolutely critical for resetting lives and livelihoods disrupted by the pandemic. Several facts suggest that this has not done while rejigging the extant vaccine strategy.

Also read: Coronavirus | Encourage patients to get vaccine, educate people against rumours: Narendra Modi to doctors

Vaccine exports

The phased roll-out of the government’s ambitious vaccination drive, beginning with health-care and frontline workers in January, followed by the gradual inclusion of senior citizens and people above 45 years in March and April, respectively, was in sync with the availability of vaccines in the country. Although SII, the largest vaccine producer, had initially promised to supply 100 million doses of vaccines a month, in reality it could provide between 50 million to 60 million doses. But, given that India too saw a degree of “vaccine-scepticism”, the Government of India found itself in a situation where it could promise exports of vaccines to 95 countries, mostly in Africa and Asia. As of April 26, these countries have received more than 66.4 million doses of vaccines from India.

Until now, nearly 142 million vaccine doses have been administered in the country, the third highest in the world. However, in terms of population share, less than 2% has received both vaccine doses, while less than 9% has received one dose. But there is one worrying facet, which is that a demand-supply mismatch has begun to appear as the coverage of the vaccine-eligible population expanded. The largest supplier, SII, gave two explanations for its inability to meet its commitments. The first was that the United States Government had used a Cold War piece of legislation, the Defense Production Act, to restrict exports of vaccine culture and other essential materials. Second, the company complained that it lacked the financial capacity to expand its production, requesting a grant of ₹30 billion from the government.

Onus on States

It is the face of this vaccine supply-crunch that the government has announced the new vaccine strategy, by opening vaccination to all adults in the country, and allowing vaccine producers to sell 50% of their production directly to State governments and private hospitals. The new strategy shifts the onus onto the State governments, which have to take decisions regarding free vaccination for people above 18 years, while the central government would continue to support vaccination for people above 45 years, and health-care workers and frontline workers. The government has not fixed the vaccine prices and has allowed the producers to pre-declare the prices they would charge from the State governments and private hospitals, a sharp departure from the extant strategy.

Thus far, government facilities have provided vaccines free of cost, while private facilities are allowed to charge no more than ₹250 per dose. The central government played the role of a sole procurement agency that helped in driving down prices, thus addressing the issue of affordable access to vaccines. However, the new strategy abandons this mechanism and fragments the market into three layers namely, central government procurement, State government procurement and the private hospitals. This layering of the market would allow the producers to charge high prices from the State governments and private hospitals. In fact, both SII and Bharat Biotech have immediately announced their intentions to raise vaccine prices. SII will sell Covishield to State governments and private hospitals would have at ₹400 and ₹600 per dose, respectively, while the corresponding figures for Bharat Biotech’s Covaxin are ₹600 and ₹1,200 per dose.

The new strategy would shift the burden of vaccination of the young population, namely, those between 18-44 years, entirely on the State governments. This implies that the vaccination of a significant section of the population depends on the financial health of each State government, resulting in inequitable access to vaccines across States. Moreover, given their poor state of finances, most State governments may not be able to procure the required number of vaccine doses to meet the demands of the targeted population. In such a situation, a large share of the vaccine quota (50% of domestic production) earmarked for the State governments and the private hospitals could end up with the latter.

In the U.S.

The decision to substantially deregulate the vaccine market raises serious questions in view of the reported advance of ₹45 billion made by the Government of India to the two vaccine producers in India for expanding their production capacities. The Federal government in the United States has done similarly, providing financial support to vaccine producers, who are now set to rake in their billions by charging high prices. Several public interest groups in the U.S. have asked questions as to why the tax-paying public should bear the high prices of vaccines when Federal taxes have been used to beef up the vaccine producers. This question is more pertinent in India, where access to affordable vaccines is critical for ensuring “vaccination for all”.

More open licensing needed

It is somewhat ironic that the new vaccine strategy, which could undermine “vaccination for all”, comes from a country that has long championed the cause of access to affordable medicines in international forums. Rather than hand over the reins of price determination to the duopoly in the vaccine market, the government should have urgently addressed the serious doubts over affordability of vaccines by ensuring a competitive market for vaccines. According to recent estimates, existing producers in India will be unable to meet the country’s vaccine requirements by some distance, and therefore, India needs more vaccine manufacturers to ensure uninterrupted supply. One positive step that the government has taken in this direction is to increase production of Bharat Biotech’s vaccine through the involvement of three public sector undertakings, including Haffkine Institute. We would argue that there is a need for more open licensing of this vaccine to scale up production. This would enhance competition in the market, enabling the vaccines to reach every citizen in the country.

Biswajit Dhar is Professor, Centre for Economic Studies and Planning, School of Social Sciences, Jawaharlal Nehru University, New Delhi. K.M. Gopakumar is Legal Adviser, Third World Network (TWN). The views expressed are personal


Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jun 22, 2021 2:16:30 AM | https://www.thehindu.com/opinion/lead/undermining-vaccination-for-all/article34417402.ece

In This Package
Focus on COVID-19 estimated deaths
What needs to be done with vaccines
Counting the dead: On measuring excess deaths
Refocused vaccination campaigns are possible
Bring genomic sequencing into the pandemic fight
Preparing for the next COVID-19 wave
Connecting the dots to mitigate a third wave
The red flags on the trail of the virus
Behaviorial change can reduce transmission
Adverse changes, federalism imperilled
Close the vaccination gap, in global lockstep
Only a global effort can tame COVID-19
Addressing vaccine hesitancy
Naturally, selection: On vaccinating the vulnerable in 18+ group
Vaccination is our only weapon
Extending safety: On deferring second dose of COVID-19 vaccine
The AIDS fight offers a COVID vaccine patent pathway
The basics of an effective vaccine policy
Using all options: On Covaxin licensing
State action: On Centre’s role in COVID-19 fight
COVID mishandling foretold in the Budget
A matter of concern: On Indian coronavirus variant
Vaccine skirmishes: On production of COVID-19 vaccine
Lockdown gains: On need to augment health system
Social murder and the missing state
A CT scan for COVID merits a word of caution
To stop a third wave, India has to mask up
Is the government committed to vaccine equity?
Salutary steps: On Election Commission norms to curb COVID-19 spread
Shortage and wastage: On cutting vaccine wastage
Gasping for air, gasping for answers
Misinformed and misleading
Right priorities: On U.S. COVID-19 aid to India
A patently wrong regime
Tips for managing COVID-19 at home: the dos & don’ts
You are reading
Undermining ‘vaccination for all’
Another wave spells more nutrition loss
Unfair and dangerous: On vaccine inequity
Viral load: On lockdowns, lives and livelihoods
The road ahead in India’s augmented vaccination drive
Infernal infernos: On hospital fires amid the pandemic
Too little: On the Election Commission’s COVID-19 curbs
India’s COVID crisis — when difficult became worse
A descent into disillusionment and chaos
Open and safe: On Modi government’s vaccination policy
A recipe for vaccine inequity
Vaccine diplomacy that needs specific clarifications
On the trail of the second wave’s dynamics
How can India contain the second wave?
Lessons from the first wave
Examination priorities: On annual exams amid the pandemic
The secrecy around deaths after vaccination
Indian universities need immediate vaccination
Lessons from COVID-19
The second wave: On why new COVID-19 vaccines should be cleared
Weighing in on the saga of a vaccine
Rising poverty: On pandemic-induced disparities
A booster shot for India’s vaccination plan
Allaying concerns: On public trust and vaccination programmes
A moral test: On the vaccine divide
Efficacious too: On Covaxin
Sustaining the drive: On COVID-19 vaccination phase 2
Vaccine inequities: On need to vaccinate all above 45
Addressing vaccine reluctance and policy hesitancy
Redefining the exit plan for COVID-19
Boosting confidence: On need for efficient use of COVID-19 vaccine stocks
Opening up the vaccine market
Origin and spread: On the source of SARS-CoV-2
New questions: On COVID-19 infecting one-fifth of Indian population
A year on, mind the gaps in the pandemic response
Should Board exams be conducted in one go this year?
No to vaccine nationalism, yes to global cooperation
Tempered optimism: On India’s sliding COVID-19 graph
The best shot against COVID-19
More vaccines than takers
Managing the rollout: On addressing vaccine hesitancy
Injecting confidence: On India’s COVID-19 vaccination drive
Vaccine optimism and the scientific uncertainty link
Building trust in vaccines
The debilitating side-effect of a flawed vaccine trial
Gearing up: On vaccines and public trust
A hurried gamble: On vaccines and transparency
The second dose: On COVID-19 vaccine
A constant vigil: On the new coronavirus strain in India
Unmasked, reflections on the pandemic and life
Caution pays: On Centre’s COVID-19 surveillance guidelines
Towards an effective vaccination distribution policy
Essential dry run: On COVID-19 vaccination drive
COVID-19 and limits of political accountability
The purpose of a vaccine
Clear the fog, draw up a clear vaccination policy
Rein in the vaccine nationalism, the profiteering
In vaccine race last lap, the key steps for India
The storage tale of two vaccines
T-cell immunity and COVID-19
COVID-19, climate and carbon neutrality
Signs of easing: On India’s COVID-19 fight
Has India passed the COVID-19 peak?
Sooner, better: On indigenously developed COVID-19 test kits
The battered Puja economy
Outline of a pandemic fight, by and for citizens
Pandemics and the collective consciousness
Vaccines with a global common good guarantee
Saving lives under the long shadow of the pandemic
Until vaccine: On Unlock 5
The challenge of changing health behaviour
Weighing the costs: On COVID-19 vaccine
The slow and frustrating journey of recovering from COVID-19
Health worker safety deserves a second look
Unlocking campuses: On UGC’s revised academic calendar
Recovery from COVID-19 can be a struggle
Uniting to combat COVID-19
Coronavirus fears and preconception advice
An agriculture-led revival as flawed claim
A necessary pause: On the COVID-19 vaccine race
The uncertainties over COVID-19 numbers
The challenges in counting the dead
COVID-19 deaths may be higher than reported
The many challenges in estimating deaths
Alone at the top: On India’s COVID-19 numbers
The participants we need in Phase 3 trials
Differential impact of COVID-19 and the lockdown
More than a vaccine, it is about vaccination
COVID-19 and a country club India must leave
A quest for order amid cyber insecurity
Adopting a public systems approach to COVID-19
Milestone of a million: On India’s COVID-19 numbers
Testing times: On university exams
Predictions, pandemics and public health
It’s time to flatten the pandemic stereotyping
Viral outrage only spikes the data
Sending the right message
Needed: Clear testing data
The social contract needs to be rewritten
The pandemic is about eyes shut
Joblessness and opportunity in Tamil Nadu
Green-lighting ecological decimation amidst a pandemic
COVID-19 has no religion
A case for extension: On rural jobs scheme
Surely, even if slowly: On a COVID-19 vaccine
Bend it like Italy: On flattening the COVID-19 curve
Promise and delivery: On India’s first COVID-19 vaccine
States hold the key: On Unlock 2.0
PCR testing is a double-edged sword
Science vs nonsense: On Patanjali’s COVID-19 claim
Shut and open: On tennis during the pandemic
The perils of follow the leader syndrome
The many questions about Favipiravir
In new lockdown, a second chance for Tamil Nadu
United front in Delhi: On Kejriwal government-Centre camaraderie
A prescription of equitable and effective care
Multilateralism post COVID-19
Making public transport safe during COVID-19
A better rate: On COVID-19 recovery
Look back in relief: On the migrant labour crisis
Needed, a transfusion for public health care
Wrong priorities: On keeping religious places open during a pandemic
Crossing the line: On Delhi’s decision to limit health services
Profit, not profiteering: On regulation of COVID-19 testing charges
In Persian Gulf littoral, cooperative security is key
Paging the private sector in the COVID fight
Curves and recoveries: On India’s coronavirus numbers
India’s Parliament is missing in action
Axing the economy’s trunk
Scripting a new narrative for COVID control
Open with caution: On Unlock 1
It’s time for a universal basic income programme in India
The waning of subaltern solidarity for Hindutva
Export blocks: On India’s trade amid the pandemic
A moment to trust the teacher
The echo of migrant footfalls and the silence on policy
Enjoying the fruits of their labour
Helping supply chains recover
The heavy burden of social suffering
An effective lockdown
The lockdown has highlighted stark inequalities
Will sport be the same in empty stadia?
Cinema after COVID-19
The eternal longing for the distant home
Working safely: On workplaces during the pandemic
A hole in the whole: On health sector woes
China, better prepared for the post-COVID world
How public health boosts an economy
Keep it retrospective
Backing the ‘angels in white coats’
Standstill: On opening of stadia for training
Flawed stimulus is justice denied
We need social physicians
A callous response
Peaking: On India’s coronavirus tally
Farm gate in focus: On amending Essential Commodities Act
A question of quarantine: On migrant workers and other travellers
TASMAC tribulations: On Tamil Nadu liquor sale
The pandemic and the challenge of behaviour change
One for the poor: On Centre’s corona package
Lockdown syndrome: On virus-induced economic crisis
Are India’s labour laws too restrictive?
Stop the return to laissez-faire
States cannot be left to the Centre’s mercy
Local motif: On Modi’s call for self-reliance
Liquidity lifeline: On Nirmala’s MSME package
A plan to revive a broken economy
Provide income support, restore jobs
Perilous state: On State finances
COVID-19 and the path ahead
Reaffirm cooperative federalism
Riding roughshod over State governments
Tragedy on the tracks: On the killing of 16 migrant workers
Coming to terms: On India refusing to admit community transmission
The trends shaping the post-COVID-19 world
The epidemic and ensuring safety in courts
Responding to COVID-19 at the grassroots
The face of exploitation
Contempt for labour: On dilution of labour laws
Slower growth and a tighter fiscal
Back home: On return of Indian expatriates
Blame game: On Donald Trump’s anti-China rhetoric over COVID-19
Resuscitating multilateralism with India’s help
A war-like state and a bond to the rescue
Fear and loathing in the land of the free
Everyone wants a good stimulus
Rent control amidst pandemic
Slow release: On lockdown 3.0
No comfort in numbers: On Bengal’s coronavirus cases
Pandemics without borders, South Asia’s evolution
India’s disease surveillance system needs a reboot
No relief for the nowhere people
BRICS against COVID-19
Recovering early: On India’s COVID-19 patients
It’s about food, nutrition and livelihood security
Taiwan’s coronavirus protocol shows how it is done
Needed: a pandemic patent pool
Getty Images/iStockphoto
Plasma therapy is no silver bullet
Take care of yourself too, fellow journalists
Strategic shift: On home isolation of mild coronavirus cases
Coping with today, planning for tomorrow
No end in sight: On India’s coronavirus strategy
Vividly imagining the life of migrant workers
A task for South Asia
Privacy concerns during a pandemic
Unlocking justice in the lockdown
Safe return: On migrant worker distress
The outline of another pandemic combat strategy
Pandemic and panic: On Tamil Nadu’s five-city lockdown
Protecting the poor from becoming poorer
Did SARS-CoV-2 begin from a lab?
Protection for protectors: On safety of healthcare workers
Rapid failures: On antibody testing kits
The COVID-19 paradox in South Asia
Fishing in troubled waters during a pandemic
How will India emerge out of the lockdown?
Making doctors wash hands
Locked out of cities, homes and livelihoods
Script of unity: On coronavirus and social prejudices
Exploiting a pandemic: On Trump’s immigration policy
The village is still relevant
A time for planetary solidarity
There may be no going back
No transparency in West Bengal
Focus on the curve: On India’s COVID-19 numbers
Economy in lockdown: On India’s worst case scenario
A shot of hope with a game changing vaccine
Caught in the heightened arc of communal polemics
Singing the corona tune
Helping a lending hand: On RBI’s second lockdown stimulus
A season of change: On IMD forecast system
A virus, social democracy, and dividends for Kerala
Across the gulf: On stranded Indian workers
Virtual reality: On telemedicine
A blueprint to revive the economy
A case to use JEE-Main instead of JEE-Advanced this year
Will the aviation industry recover from the pandemic?
Data-driven reporting during COVID-19
Stress test: On revised lockdown guidelines
Disastrous decision: On Trump halting funds to WHO
Cease the distractions, seize the moment
Getting the containment strategy in India right
In India’s response, a communications failure
Harmonising with nature
End the harassment of farmers now
A narrowing window: On extension of lockdown
Corona bond: On Eurozone COVID-19 rescue package
Halting the march of rumours
Polls during a pandemic
The pandemic and the contours of a health response
Economic liberalisation and its faults
Invasive, alien, most fearsome
Trade in tatters: On the global slump
Wanted, a collective national endeavour
Disingenuous and no antidote
COVID-19 and the crumbling world order
Women’s safety during lockdown
Lives and livelihoods: On economy after lockdown
Stage fright: On denying community transmission
Team India and winning the pandemic battle
In time of need: On hydroxychloroquine export
Will COVID-19 affect the course of globalisation?
Finding a scapegoat in WHO
Curating news for children during pandemic
A time for extraordinary action
For better use: On MPLADS funds
Needed, greater decentralisation of power
A key arsenal in rural India’s pandemic fight
Preparing for exit: On lifting the lockdown
Sanctions and pandemic: On America’s Iran policy
‘A script of action, responsibility and compassion’: Chief Minister Ashok Gehlot writes on Rajasthan’s fight against COVID-19
Taking a long view of the pandemic fight
Ten questions posed by the virus
A different economic approach
Why healthcare workers above 60 should be ‘benched’
Enemy at the gates: On Kerala-Karnataka border row
Reducing farm distress during a pandemic
Why everyone should wear masks
The criticality of community engagement
A niggardliness that is economically unwarranted
The spectre of a post-COVID-19 world
Light and sound: On Narendra Modi’s 9-minute light ceremony
A million and counting: On global coronavirus spread
Safe forests, safe people: On diseases of animal origin
Quarantine and the law
Making the private sector care for public health
Looking east to contain COVID-19
Limits to rugged individualism
Uncritical endorsement: On exodus of migrant workers and the Supreme Court
Beyond the blame game: On the Tablighi Jamaat episode
A long road: On India’s 21-day coronavirus lockdown
The missing notes: On politics and the fight against COVID-19
China’s zero: On China’s lead in containing coronavirus
Unprecedented step: On Wuhan lockdown
The return of the expert
Lessons from Hubei
A pandemic in an unequal India
Faith can’t override public health
Devising a people-centric response to COVID-19
Karnataka CM writes on how the State is fighting the pandemic
Tamil Nadu CM writes on how the State is stopping the pandemic in its tracks
The hunt for a cure begins with telling the truth
COVID-19 and a city’s anatomy
Long live the nation-state
The COVID cycle
Coronavirus | The worst of times, the best of times
It’s also a fight against punitive measures
The age of the neoliberal virus
The deep void in global leadership
Thinking national, acting local
Every man is a part of the main
Beyond social distancing to fight COVID-19
Next Story